Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$2.99

52W Range

$2.66 - $18.07

50D Avg

$3.42

200D Avg

$7.86

Market Cap

$223.06M

Avg Vol (3M)

$2.07M

Beta

1.74

Div Yield

-

ZNTL Company Profile


Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

124

IPO Date

Apr 03, 2020

Website

ZNTL Performance


ZNTL Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-299.51M$-227.29M$-216.54M
Net Income$-292.19M$-220.83M$-164.26M
EBITDA$-299.51M$-233.27M$-268.52M
Basic EPS$-4.47$-4.18$-3.85
Diluted EPS$-4.47$-4.18$-3.85

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
OLMAOlema Pharmaceuticals, Inc.
SANASana Biotechnology, Inc.
KYMRKymera Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
VECTVectivBio Holding AG
RVMDRevolution Medicines, Inc. Warrant
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
ERASErasca, Inc.
SNDXSyndax Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
ANNXAnnexon, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
ITOSiTeos Therapeutics, Inc.
PTGXProtagonist Therapeutics, Inc.
LIFEaTyr Pharma, Inc.